Perspective on the osteoclast: An angiogenic cell?

Annals of the New York Academy of Sciences

Volumn 1117, Issue , 2007, Pages 12-25

  Cackowski, Frank C ^a   Roodman, G David ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Bone; Osteoclast

Indexed keywords

ALENDRONIC ACID; ANGIOGENIC FACTOR; BISPHOSPHONIC ACID DERIVATIVE; NERIDRONIC ACID; NITROGEN; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL; BONE STRUCTURE; CELL STIMULATION; CONFERENCE PAPER; ENDOTHELIUM CELL; FEASIBILITY STUDY; FRACTURE HEALING; HUMAN; MACROPHAGE; NONHUMAN; OSTEOCLAST;

EID: 36549007498     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1402.073     Document Type: Conference Paper

References (85)

1. BRANDI, M.L. & P. COLLIN-OSDOBY. 2006. Vascular biology and the skeleton. J. Bone Miner. Res. 21: 183-192.
2. RIBATTI, D., B. NICO & A. VACCA. 2006. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 25: 4257-4266.
3. TANAKA, Y. et al. 2007. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin. Cancer Res. 13: 816-823.
4. COXON, F.P., K. THOMPSON & M.J. ROGERS. 2006. Recent advances in understanding the mechanism of action of bisphosphonates. Curr. Opin. Pharmacol. 6: 307-312.
5. CROUCHER, P.I. et al. 2003. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner. Res. 18: 482-492.
6. LAMAGNA, C., M. AURRAND-LIONS & B. A. IMHOF. 2006. Dual role of macrophages in tumor growth and angiogenesis. J. Leukoc. Biol. 80: 705-713.
7. CARANO, R.A. & E.H. FILVAROFF. 2003. Angiogenesis and bone repair. Drug Discov. Today 8: 980-989.
8. DECKERS, M.M. et al. 2002. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143: 1545-1553.
9. MARRONY, S. et al. 2003. Bone morphogenetic protein 2 induces placental growth factor in mesenchymal stem cells. Bone 33: 426-433.
10. AKENO, N. et al. 2002. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. Endocrinology 143: 420-425.
11. HARADA, S. et al. 1994. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J. Clin. Invest. 93: 2490-2496.
12. ESCOBAR, E. et al. 2004. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr. Vasc. Pharmacol. 2: 385-399.
13. MUIR, C. et al. 2006. Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells. Clin. Exp. Metas. 23: 75-86.
14. WANG, Y. et al. 2007. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J. Clin. Invest. 117: 1616-1626.
15. BOULETREAU, P.J. et al. 2002. Factors in the fracture microenvironment induce primary osteoblast angiogenic cytokine production. Plast. Reconstr. Surg. 110: 139-148.
16. BLANQUAERT, F., R.C. PEREIRA & E. CANALIS. 2000. Cortisol inhibits hepatocyte growth factor/scatter factor expression and induces c-met transcripts in osteoblasts. Am. J. Physiol. Endocrinol. Metab. 278: E509-E515.
17. TOKUDA, H. et al. 2003. Involvement of MAP kinases in TGF-[beta]-stimulated vascular endothelial growth factor synthesis in osteoblasts. Arch. Biochem. Biophys. 415: 117-125.
18. KASAMA, T. et al. 2007. Expression of angiopoietin-1 in osteoblasts and its inhibition by tumor necrosis factor-alpha and interferon-gamma. Trans. Res. 149: 265-273.
19. GLOWACKI, J. 1998. Angiogenesis in fracture repair. Clin. Orthop. Relat. Res. S82-S89.
20. GARTNER, L.P. & J.L. HIATT. 2001. Color Textbook of Histology. W.B. Saunders. Philadelphia.
21. BURKHARDT, R. et al. 1984. The structural relationship of bone forming and endothelial cells of the bone marrow. In Bone Circulation. J. Arlet, R.P. Ficat & D.S. Hungerford, Eds.: 2-14. Williams & Wilkins, Baltimore, MD.
22. HAUGE, E.M. et al. 2001. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J. Bone Miner. Res. 16: 1575-1582.
23. PARFITT, A.M. 2000. The mechanism of coupling: a role for the vasculature. Bone 26: 319-323.
24. BARON, R. 2003. Anatomy and biology of bone matrix and cellular elements. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. M.J. Flauus, Ed.: 1-8. American Society for Bone and Mineral Research. Washington, DC.
25. KUZNETSOV, S.A. et al. 2001. Circulating skeletal stem cells. J. Cell Biol. 153: 1133-1140.
26. ENGSIG, M.T. et al. 2000. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J. Cell Biol. 151: 879-890.
27. STREET, J. et al. 2002. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. PNAS 99: 9656-9661.
28. YAMAZAKI, M. et al. 1999. Spatial and temporal distribution of CD44 and osteopontin in fracture callus. J. Bone Joint Surg. Br. 81: 508-515.
29. HIRAKAWA, K. et al. 1994. Localization of the mRNA for bone matrix proteins during fracture healing as determined by in situ hybridization. J. Bone Miner. Res. 9: 1551-1557.
30. DUVALL, C.L. et al. 2007. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. J. Bone Miner. Res. 22: 286-297.
31. SAIJO, M. et al. 2003. Heparanase mRNA expression during fracture repair in mice. Histochem. Cell Biol. 120: 493-503.
32. FINDLAY, D.M. & D.R. HAYNES. 2005. Mechanisms of bone loss in rheumatoid arthritis. Mod. Rheumatol. 15: 232-240.
33. COLLIN-OSDOBY, P. et al. 2002. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J. Bone Miner. Res. 17: 1859-1871.
34. COLLIN-OSDOBY, P. et al. 2000. Decreased nitric oxide levels stimulate osteoclastogenesis and bone resorption both in vitro and in vivo on the chick chorioallantoic membrane in association with neoangiogenesis. J. Bone Miner. Res. 15: 474-488.
35. COLLIN-OSDOBY, P. et al. 2001. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276: 20659-20672.
36. KINDLE, L. et al. 2006. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts. J. Bone Miner. Res. 21: 193-206.
37. HAMMER, F. et al. 2005. Gorham-Stout disease- stabilization during bisphosphonate treatment. J. Bone Miner. Res. 20: 350-353.
38. DEVLIN, R.D., H.G. BONE, III & G.D. ROODMAN. 1996. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J. Clin. Endocrinol. Metab. 81: 1893-1897.
39. COLUCCI, S. et al. 2006. Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. J. Bone Miner. Res. 21: 207-218.
40. GIULIANI, N. et al. 2003. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102: 638-645.
41. COLLA, S. et al. 2005. Human myeloma cells express the bone regulating gene Runx2//Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 19: 2166-2176.
42. WAI, P.Y. & P.C. KUO. 2004. The role of osteopontin in tumor metastasis. J. Surg. Res. 121: 228-241.
43. KIESEL, K. et al. 2007. Systems level analysis of osteoclastogenesis reveals intrinsic and extrinsic regulatory interactions. Dev. Dynam. 236: 2181-2197.
44. KIM, Y.M. et al. 2002. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J. Biol. Chem. 277: 6799-6805.
45. DAY, C. et al. 2004. Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor. J.Cell. Biochem. 91: 303-315.
46. CAPPELLEN, D. et al. 2002. Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J. Biol. Chem. 277: 21971-21982.
47. ISHIDA, N. et al. 2002. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 277: 41147-41156.
48. KUBOTA, K., K. WAKABAYASHI & T. MATSUOKA. 2003. Proteome analysis of secreted proteins during osteoclast differentiation using two different methods: two-dimensional electrophoresis and isotope-coded affinity tags analysis with two-dimensional chromatography. Proteomics 3: 616-626.
49. CZUPALLA, C. et al. 2005. Comparative study of protein and mRNA expression during osteoclastogenesis. Proteomics 5: 3868-3875.
50. NOMIYAMA, H. et al. 2005. Short communication: Identification of genes differentially expressed in osteoclast-like cells. J. Interferon Cytok. Res. 25: 227-231.
51. RHO, J. et al. 2002. Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization (SSH) and cDNA microarray analysis. DNA Cell Biol. 21: 541-549.
52. HAUSCHKA, P.V. et al. 1986. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J. Biol. Chem. 261: 12665-12674.
53. SEYEDIN, S.M. et al. 1986. Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta. J. Biol. Chem. 261: 5693-5695.
54. PFEILSCHIFTER, J. & G.R. MUNDY. 1987. Modulation of type {beta} transforming growth factor activity in bone cultures by osteotropic hormones. PNAS 84: 2024-2028.
55. DALLAS, S.L. et al. 2002. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277: 21352-21360.
56. OREFFO, R.O.C. et al. 1989. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem. Biophys. Res. Commun. 158: 817-823.
57. MYSTAKIDOU, K. et al. 2005. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates. Cancer Treat. Rev. 31: 303-311.
58. WOOD, J. et al. 2002. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302: 1055-1061.
59. HASHIMOTO, K. et al. 2007. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem. Biophys. Res. Commun. 354: 478-484.
60. RIBATTI, D. et al. 2007. Neridronate inhibits angiogenesis in vitro and in vivo. Clin. Rheumatol. 26: 1094-1098.
61. CHEN, T. et al. 2002. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 42: 1228-1236.
62. SATO, M. et al. 1991. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88: 2095-2105.
63. COXON, F.P. et al. 2005. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 37: 349-358.
64. SUZUKI, K. et al. 2006. Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J. Pharmacol. Sci. 100: 189-194.
65. ROSS, F.P. & S.L. TEITELBAUM. 2005. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol. Rev. 208: 88-105.
66. HALASY-NAGY, J.M., G.A. RODAN & A.A. RESZKA. 2001. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29: 553-559.
67. XING, L. & E. SCHWARZ. 2005. Circulating osteoclast precursors: a mechanism and a marker of erosive arthritis. Curr. Rheumatol. Rev. 1: 21-28.
68. ARAI, F. et al. 1999. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor {kappa}B (RANK) receptors. J. Exp. Med. 190: 1741-1754.
69. LEWIS, J.S. et al. 1999. Macrophage responses to hypoxia: relevance to disease mechanisms. J. Leukoc. Biol. 66: 889-900.
70. WHITE, J.R. et al. 2004. Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics 83: 1-8.
71. KUWABARA, K. et al. 1995. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc. Natl. Acad. Sci. USA 92: 4606-4610.
72. XIONG, M. et al. 1998. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am. J. Pathol. 153: 587-598.
73. LEIBOVICH, S.J. et al. 1987. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-[alpha]. Nature 329: 630-632.
74. KOCH, A.E. et al. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798-1801.
75. TOMBRAN-TINK, J. & C.J. BARNSTABLE. 2004. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. Biochem. Biophys. Res. Commun. 316: 573-579.
76. HORNER, A. et al. 2001. Tie2 ligands angiopoietin-1 and angiopoietin-2 are coexpressed with vascular endothelial cell growth factor in growing human bone. Bone 28: 65-71.
77. ROTHE, L. et al. 1998. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology 139: 4353-4363.
78. MILLS, B.G. & A. FRAUSTO. 1997. Cytokines expressed in multinucleated cells: Paget's disease and giant cell tumors versus normal bone. Calcif. Tissue Int. 61: 16-21.
79. GRANO, M. et al. 1996. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. PNAS 93: 7644-7648.
80. GUPTA, D. et al. 2001. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950-1961.
81. CHOU, J.M., C.-Y. LI & A. TEFFERI. 2003. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. Leuk. Res. 27: 499-504.
82. BIRCH, M.A. et al. 1993. PCR detection of cytokines in normal human and pagetic osteoblast-like cells. J. Bone Miner. Res. 8: 1155-1162.
83. RYDZIEL, S., S. SHAIKH & E. CANALIS. 1994. Platelet-derived growth factor-AA and -BB (PDGF-AA and -BB) enhance the synthesis of PDGF-AA in bone cell cultures. Endocrinology 134: 2541-2546.
84. GLOBUS, R.K., J. PLOUET & D. GOSPODAROWICZ. 1989. Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix. Endocrinology 124: 1539-1547.
85. WANG, F.-S. et al. 2004. Ras induction of superoxide activates ERK-dependent angiogenic transcription factor HIF-1{alpha} and VEGF-A expression in shock wave-stimulated osteoblasts. J. Biol. Chem. 279: 10331-10337.